Clinical Trial Update: Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a monoclonal antibody therapy for low-grade non-Hodgkin's lymphoma sponsored by Amgen has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Unnamed monoclonal antibody therapy

Snippet

Sponsor: Amgen | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED